Navigation Links
Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
Date:6/19/2009

al of six injections, could offer an important treatment option if it demonstrates safety and efficacy comparable to peginterferon alfa-2a dosed once every week with a total of 24 injections."

About the Design of the Phase 2b Monthly Dosing Trial

This Phase 2b trial is a randomized, open-label, multi-center, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every four weeks plus daily ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. 391 patients were randomized in a 4:4:4:3 ratio into four treatment groups, including three that will receive albinterferon alfa-2b administered once every four weeks (900 mcg, 1200 mcg or 1500 mcg), in addition to the active-control group, which will receive peginterferon alfa-2a at the standard 180-mcg dose once every week. All patients in the study will receive 800-mg daily oral ribavirin. The total duration of treatment will be 24 weeks. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.

The Company's primary focus is rapid progress toward the commercialization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. Albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are ongoing, with results expected in July and November 2009.

In April 2009, HGS completed delivery of 20,000 doses of raxibacum
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Oro Valley, Arizona (PRWEB) September 16, 2014 ... company that develops safe and effective products to ... through the use of a proprietary SPACEā„¢ Technology ... Executive Officer and President will present at the ... 18, 2014 at the Hyatt Regency Phoenix. ...
(Date:9/16/2014)... 2014  Ascendis Pharma A/S, a biotechnology company ... significant unmet medical needs, today announced positive interim ... to evaluate once-weekly TransCon Growth Hormone in children ... interim results will be presented at the 7th ... being held October 15-18, 2014, in Singapore.  ...
(Date:9/16/2014)... Canada (PRWEB) September 16, 2014 According ... the Toronto affiliate of ITRA Global, new development in ... the Toronto city council approving another 755 storeys of ... it appears construction cranes will be dominating the Toronto ... seems to have an unquenchable thirst for new development. ...
(Date:9/15/2014)... , Sept. 15, 2014   Global ... innovator of scientific products and services for satellite ... Acquisition Solution for Integrated Services (OASIS) from the ... GST was selected to provide the government best-value ... Small Business (SB) category in Pool 4. The ...
Breaking Biology Technology:Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... results in physician,s office -, MADISON, N.J., ... Quest Diagnostics Incorporated (NYSE: DGX ),today announced ... T(TM) fecal,immunochemical test, a point-of-care version of the ... the sensitivity and,specificity of the laboratory-based InSure FIT ...
... Announces CE Mark Approval for First Product, the CorMatrix ... ECM(TM) for ... an,Atlanta- based company dedicated to developing and delivering unique,extracellular matrix ... damaged cardiovascular tissue, announced,today that the company has received 510(k) ...
... Pursues Strategy of Reducing Heart Attack Deaths by Shielding ... High-Risk Plaques ... Prescient Medical, Inc., a,privately held medical device company dedicated ... results on the chemical,characterization and treatment of rupture-prone or ...
Cached Biology Technology:Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 3Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 4Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 5CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 2CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 3CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 4Prescient Medical, Inc. to Present Data on Identification and Treatment of Rupture-Prone Coronary Plaques at EuroPCR 2008 2
(Date:9/16/2014)... year, a new football season and another commercial cargo ... Dragon spacecraft is scheduled to blast off to the ... the company,s fourth contracted mission to the complex. , ... of research investigations sponsored by the Center for the ... of managing the U.S. National Laboratory on the space ...
(Date:9/16/2014)... A complex web of interaction between viruses, bacteria, ... by a growing international collaboration between Matthew Sullivan, ... of Ecology and Evolutionary Biology and Steven Hallam ... Canada. , "Bacteria are drivers of nutrient ... said. "As the climate is changing, so are ...
(Date:9/16/2014)... (KXL) would likely increase oil sands extraction, according to ... non-profit organization Near Zero. The results are detailed in ... both supporters and opponents of the pipeline. ... to significantly higher greenhouse gas emissions, with the exact ... "This report examines three main scenarios discussed by participants ...
Breaking Biology News(10 mins):CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... the University of California, Riverside are part of a ... living bacteria a discovery that could help in ... The research team believes this is the first ... biological rather than chemical means. It opens the door ...
... teaming up with colleagues in other higher education institutions ... courses. They include research into a mobile biosensor, ... sports, and a manufacturing process to make titanium golf ... seven collaborative studentships, currently underway in the East Midlands. ...
... a diesel engine is far from easy. Due to ... combustion cycles are the same. Furthermore, the measurements are ... is injected into the cylinder causes an extra source ... cylinder with an engine adapted for this purpose. ...
Cached Biology News:Nanotube-producing bacteria show manufacturing promise 2
... Plates are designed for quick and easy ... plates feature two 0.25mm holes laser cut ... The wells remain liquid-tight during incubation of ... time the protein diffuses from the gel ...
... is a direct antibiotic-based ... identification. Recombinant selection depends ... eliminating the need for ... quick and inexpensive process ...
... Enhancer does for enzyme-/substrate-based blotting what intensifying screens ... signal up to 10-fold (or one order of ... Blot Signal Enhancer membrane treatment is a simple, ... your current Western blotting protocol. The result is ...
... a multi-functional program that searches ... a sequence file for polymerase ... site-directed mutagenesis, and various hybridization ... and secondary structure of oligonucleotides ...
Biology Products: